GFRα3 is a GPI-linked GDNF-family co-receptor that binds artemin and forms a signaling complex with RET to support sensory and sympathetic neurons
[1]. Mechanistically, the ARTN-GFRα3 complex initiates formation of a ternary receptor complex containing shared RET, linking ligand recognition to downstream neurotrophic signaling
[2]. In sensory biology, GFRα3 marks nociceptive dorsal root ganglion neurons that coexpress RET, TRPV1, TrkA, peripherin, and CGRP, distinguishing an artemin-responsive nociceptor subset from the GDNF-responsive population
[3]. Artemin and other GDNF-family ligands sensitize thermal nociceptors, while artemin shows particular relevance to inflammatory hyperalgesia
[4]. In pain models, GFRα3 is required for inflammatory and neuropathic cold allodynia, and artemin-GFRα3 signaling acts through TRPM8-dependent cold-pain mechanisms
[5][6]. Compared with related isoforms, GFRα3 differs from GFRα1 because GFRα1 is highly selective for GDNF rather than artemin
[7]. For experimental applications, anti-GFRα3 monoclonal antibodies reduced evoked allodynia and thermal hyperalgesia in mouse joint-pain models, but REGN5069 did not improve knee osteoarthritis pain in a phase 2 trial
[8].